{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:08:26Z","timestamp":1772060906732,"version":"3.50.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership","award":["TMA2016CDF-1580"],"award-info":[{"award-number":["TMA2016CDF-1580"]}]},{"name":"EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership","award":["RIA2016MC-1606-VirTUAL"],"award-info":[{"award-number":["RIA2016MC-1606-VirTUAL"]}]},{"name":"HHS | NIH | NIH Office of the Director","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}]},{"DOI":"10.13039\/501100000360","name":"Scottish Funding Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000360","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>We characterized the pharmacokinetics of standard- and high-dose rifampicin in Ugandan adults with tuberculosis and HIV taking dolutegravir- or efavirenz-based antiretroviral therapy. A liver model with saturable hepatic extraction adequately described the data, and the increase in exposure between high and standard doses was 4.7-fold. This was lower than what previous reports of dose-exposure nonlinearity would predict and was ascribed to 38% lower bioavailability of the rifampicin-only top-up formulation compared to the fixed-dose combination.<\/jats:p>","DOI":"10.1128\/aac.00431-23","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:42:55Z","timestamp":1697632975000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5084-4314","authenticated-orcid":false,"given":"Allan","family":"Kengo","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamunkhwala","family":"Gausi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Nabisere","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Musaazi","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Omali","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud university medical center , Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Centre , Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek James","family":"Sloan","sequence":"additional","affiliation":[{"name":"Division of Infection and Global Health, School of Medicine, University of St. Andrews , Scotland, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Sekaggya-Wiltshire","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix247"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00955-2020"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2524OC"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Denis A M\n. 2005. Shortening the treatment of tuberculosis. Available from: http:\/\/www.nature.com\/naturebiotechnology. https:\/\/doi.org\/10.1038\/nbt0205-187","DOI":"10.1038\/nbt0205-187"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1071"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac585"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab162"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00140-21"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4132-7"},{"key":"e_1_3_3_16_2","unstructured":"WHO\n. 2021. Global tuberculosis report 2021"},{"key":"e_1_3_3_17_2","first-page":"9","volume-title":"Manajemen Asuhan Kebidanan Pada Bayi Dengan caput Succedaneum Di Rsud Syekh Yusuf Gowa Tahun","author":"Beal S","year":"1989","unstructured":"Beal S , Boeckmann A , Sheiner L . 1989. NONMEM user guides. Icon development solutions, Elliot city, p 9\u201315. In Manajemen Asuhan Kebidanan Pada Bayi Dengan caput Succedaneum Di Rsud Syekh Yusuf Gowa Tahun"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01830-15"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v5.i6.525"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.05.056"},{"key":"e_1_3_3_22_2","first-page":"356","article-title":"Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa","volume":"6","author":"McIlleron H","year":"2002","unstructured":"McIlleron H , Wash P , Burger A , Folb P , Smith P . 2002. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 6:356\u2013361.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0833"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02174-18"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.5897\/AJPP2013.3754"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0833"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016212804288"},{"key":"e_1_3_3_28_2","unstructured":"Purdie FP FDA CDER\n. 2017. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry. Internet. Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2003.11.031"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab908"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05526-11"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00431-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00431-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T14:05:29Z","timestamp":1700057129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00431-23"}},"subtitle":[],"editor":[{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,15]]}},"alternative-id":["10.1128\/aac.00431-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00431-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"2023-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00431-23"}}